Raji In Vivo Anti-Tumor Efficacy Assay

This assay is to provide Raji-based In Vivo Anti-Tumor Efficacy Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

Raji

Human

Raji cells were derived from the B-lymphocytes of an 11-year-old Nigerian Burkitt's lymphoma male patient in 1963 by R.J.V. Pulvertaft and was further worked on by B.O. Osunkoya (University College Hospital, Ibadan, Nigeria). The Raji cell line is categorized as lymphoblast-like.

B Lymphoma

Oncology

In Vivo Anti-Tumor Efficacy Assay

Raji-cell based In Vivo Anti-Tumor Efficacy Assay

After positive anti-tumor efficacy data is concluded using in vitro assays, we can start to initiate in vivo anti-tumor efficacy studies. Creative Biolabs offers a wide variety of PDX or CDX models to facilitate the efficacy studies. This assy will be used to evaluate the anti-tumor efficacy of your therapeutic candidates, such as small molecules, antibodies, CARTs or other biologics. Detailed group set up and other plans will be discussed according to your specific requirements.

Oncology In Vivo Assays